课题基金 / 基金详情

项目摘要

项目成果

Michael Tilghman Treadway的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Anhedonia and reduced motivation for reward are core symptoms of major depressive disorder (MDD). However, standard antidepressant treatments - which primarily target the serotonergic system - have been found to be less successful at addressing these symptoms. A significant body of evidence from preclinical studies suggests that the neurotransmitter dopamine (DA) plays a crucial role in motivating an organism to expend effort in pursuit of reward. Furthermore, reduced DAergic function and decreased DA turnover have long been associated with major depression, though the specific clinical effects of this altered DAergic function remain unclear. The specific aims of this project are to elucidate behavioral deficits in effort-based decision making and accompanying alterations in DAergic function and cortico-striatal circuitry in healthy subjects and individuals with MDD. To achieve this, we have developed a novel behavioral test of effort-based decision making. This test was adapted from a well-validated animal paradigm that has been used extensively to characterize the impact of cortical lesions and DA blockade on effort-based decision making in rats. Using this paradigm, we have collected preliminary data suggesting that reduced effort-expenditure is associated with trait-anhedonia in healthy controls. We propose to run this task with a group of healthy control subjects who will undergo serial PET scans using the D2/D3 receptor ligand [18F] Fallypride during both a baseline timepoint and during an amphetamine challenge. In addition, we will use this task in a sample of individuals with Major Depressive Disorder and reported anhedonic symptoms and a sample of age, gender and handedness matched controls during an fMRI scan. PUBLIC HEALTH RELEVANCE: Symptoms of anhedonia and reduced motivation in MDD are a significant component of the disorder, but specific treatments for these symptoms are lacking. By providing a specific behavioral model of reduced effort-expenditure that may be linked to alterations in DAergic transmission and cortico-striatal circuitry, this research has the potential to identify novel targets for the treatment of anhedonia in depression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Glutamatergic adaptation to stress as a mechanism for anhedonia and treatment response with ketamine
  • 批准号:
    10375849
  • 项目类别:
  • 资助金额:
    $77.88万
  • 财政年份:
    2022
  • 负责人:
    Michael Tilghman Treadway
  • 依托单位:
Glutamatergic adaptation to stress as a mechanism for anhedonia and treatment response with ketamine
  • 批准号:
    10571930
  • 项目类别:
  • 资助金额:
    $76.23万
  • 财政年份:
    2022
  • 负责人:
    Michael Tilghman Treadway
  • 依托单位:
Transdiagnostic and Disorder-Specific Effects of Immune and Metabolic Factors on Motivational Deficits Across Mood and Psychotic Disorders
  • 批准号:
    9979349
  • 项目类别:
  • 资助金额:
    $42.9万
  • 财政年份:
    2020
  • 负责人:
    Michael Tilghman Treadway
  • 依托单位:
Dynamics of Inflammation and its Blockade on Motivational Circuitry in Depression
  • 批准号:
    9318578
  • 项目类别:
  • 资助金额:
    $41.01万
  • 财政年份:
    2016
  • 负责人:
    Michael Tilghman Treadway
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: